Sierra Oncology is a late-stage biopharmaceutical company focused on delivering targeted therapies for rare forms of cancer, particularly myelofibrosis
Sierra Oncology is a late-stage biopharmaceutical company focused on delivering targeted therapies for rare forms of cancer, particularly myelofibrosis. Their lead product candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor currently under investigation in clinical trials.